<DOC>
	<DOCNO>NCT02707328</DOCNO>
	<brief_summary>This study look determine maximum safe dose CyberKnife give chemotherapy unresectable adenocarcinoma pancreas .</brief_summary>
	<brief_title>Study To Establish Maximum Tolerated Dose ( MTD ) Cyberknife Patients With Un-Resectable Pancreas Cancer ( TL002 )</brief_title>
	<detailed_description>The purpose study determine MTD radiosurgery treatment unresectable pancreas cancer , MTD use future phase II III study . In term start dose phase I study , base low toxicity see Moffitt study feel 30 Gy five fraction successful start dose . Most data unresectable derived patient metastatic set term chemotherapy agent . There two major study look various chemotherapy regimen versus previous standard care Gemzar . One study find improved survival FOLFIRINOX second find combination nab-paclitaxel gemzar superior gemzar alone . Thus , current standard care metastatic pancreas cancer ( local therapy like radiation limited role ) either FOLFIRINOX gemzar nab-paclitaxel . While discussion randomize study compare FOLFIRINOX gemzar combine nab-paclitaxel study start time unclear much interest would accrue study . Therefore exact best chemotherapy regimen metastatic disease unclear either FOLFIRIONX gemzar-nab-paclitaxel . The chemotherapy regimens unresectable cancer extrapolate metastatic setting , per NCCN guideline chemotherapy regimen approve metastatic disease reasonable use unresectable pancreas cancer . Thus purpose study choose one two chemotherapy regimen show best result metastatic setting , since way determine exact best regimen choose gemzar nab-paclitaxel since felt less toxic regimen compare FOLFIRINOX .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Pathologically confirm adenocarcinoma pancreas Unresectable disease base follow image criterion ( table 1 ) extrapancreatic extension tumor involvement SMA celiac axis evidence occlusion SMVportal vein confluence KPS &gt; 50 ( ECOG 02 ) Age &gt; 18 year Women childbearing age male participant must practice adequate contraception ( hormonal barrier method birth control ; abstinence ) prior throughout study treatment . Life expectancy &gt; 3 month Ability understand willingness sign write informed consent . Note patient metastatic disease eligible felt patient benefit local control primary disease . Disease measureable evaluable response endpoint per RECIST Prior radiotherapy upper abdomen Resectable borderline resectable pancreas cancer . Note patient eligible separate study look radiosurgery borderline resectable pancreas cancer Severe comorbidity render candidate ineligible chemotherapy radiation , Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients childbearing age unwilling unable practice contraception Inability undergo MRI CT contrast treatment plan Patients may receive investigational commercial agent therapeutic intent treat pancreatic cancer trial . Note patient previous investigational therapy concurrently protocol treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>CyberKnife</keyword>
	<keyword>Cyber knife</keyword>
	<keyword>CK</keyword>
	<keyword>abraxane</keyword>
	<keyword>nab-paclitaxel</keyword>
</DOC>